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eration of the action potential and excitation-contraction
coupling. The most common electrophysiologic abnor-
mality is a prolongation of the action potential. A repre-
sentative action potential from a normal and failing
human myocyte is shown in Fig 1. Membrane repolar-
ization is initiated by the K+ efflux of the delayed recti-
fier current, which is later joined by an additional out-
ward K+ current to return the sarcolemma to the resting
membrane potential.4 The prolongation of the action
potential with hypertrophy and/or failure is likely due to
alterations in key sarcolemmal channels and currents
that contribute to the action potential repolarization.
Specifically, the delayed rectifier current, which is
directly responsible for repolarization, is reduced in
myocardial hypertrophy5,6 and has been associated with
a prolongation of the action potential.7,8 With the use of
gene transfection techniques, enhanced production of K+
channels that contribute to the delayed rectifier current
has been shown to correct action potential prolonga-
tion.9 This observation supports the ionic basis for
changes in action potential morphology, including
defects in K+ currents that are operable during action
potential repolarization. The prolongation of the action
potential in hypertrophy and/or failure may result in
early depolarization, which may create a re-entry circuit,
thereby promoting arrhythmias.10,11 The Na+/K+ adeno-
sine triphosphatase (ATPase), which contributes to the
maintenance of the resting action potential, is altered in
severe hypertrophy and/or failure12-14 and may con-
tribute to a more positive and unstable resting potential.
These molecular defects that contribute to changes in the
action potential with hypertrophy and/or failure may
have particular relevance to the development of ventric-
ular arrhythmias after cardiac operations.15
Excitation-contraction coupling
Normal myocyte contraction depends on a highly
organized sequence of molecular and mechanical events
between the sarcolemma, the sarcoplasmic reticulum
(SR), and the contractile apparatus. After sarcolemmal
D espite significant improvements in the intraoperativemanagement of patients undergoing cardiac surgery,
postoperative left ventricular (LV) pump dysfunction
occurs and often requires inotropic and/or vasodilator
therapy. This LV pump dysfunction can contribute to a
complex postoperative course.1,2 It is likely that the
number of cardiac surgical procedures, such as coronary
artery bypass grafting (CABG), will increase in the
future due to several factors. First, the relative number of
patients surviving an initial myocardial infarction and
the relative proportion of elderly patients have both
increased and therefore may ultimately require CABG.3
The purpose of this review is to place these conditions in
the context of cardiac surgery with particular emphasis
on the ischemia/reperfusion injury that may occur dur-
ing the intraoperative period. Although a number of sys-
temic and neurohormonal factors clearly influence LV
pump function and hemodynamics in the postoperative
setting, this review will focus on basic systems within
the cardiac myocyte that are altered in hypertrophy
and/or failure, which may in turn influence contractility
in the perioperative setting. This review will be a struc-
ture-function presentation in which the myocyte will be
dissected into key structural components that are direct-
ly related to contractile performance.
Sarcolemmal systems
The sarcolemma contains channels and energy-depen-
dent pumps that play a fundamental role in both the gen-
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depolarization, the L-type Ca2+ channel becomes acti-
vated, resulting in a Ca2+ current across the sarcolemma,
which activates the calcium release channels of the SR,
as shown in Fig 2. After calcium release channel activa-
tion, a bolus release of Ca2+ from the SR engages the
myofilament apparatus, resulting in sarcomere shorten-
ing. The return to resting sarcomere length is an energy-
dependent process that has been termed active relax-
ation.4 Active relaxation primarily consists of the
re-uptake of intracellular Ca2+ by SR Ca2+ ATPase
(SERCA-2), thus reducing the concentration of intracel-
lular Ca2+. For the purposes of this review, specific alter-
ations in excitation-contraction coupling that occur in
hypertrophy and/or failure will be divided into two
events: contraction and active relaxation. 
Contraction. Since Ca2+ influx through the L-type
Ca2+ channel is the initial trigger for excitation-con-
traction coupling, a defect in function and/or density
will alter myocyte contractility.16,17 Accordingly, the
function of the L-type Ca2+ channel has been the focus
of several investigations.17-20 The majority of these
studies have reported a reduction in L-type Ca2+ current
and/or channel density in hypertrophied and/or failing
myocytes. For example, Mukherjee and associates16
reported a decrease in L-type Ca2+ current that was
associated with intrinsic defects in contractile function
with the development of pacing-induced heart failure.
The peak levels of Ca2+ released into the cytosolic com-
partment have been demonstrated to be decreased in
severe hypertrophy and/or failure.21 The Ca2+ dis-
charged from the SR binds to troponin C, resulting in
conformation changes of the contractile apparatus.
These changes allow for myofilament cross-bridge for-
mation and, thus, myocyte shortening. A decrease in
SR Ca2+ release would inhibit the ability of the myofil-
ament apparatus to undergo the conformational
changes necessary for cross-bridge formation. Second,
the absolute reduction of Ca2+ will result in a dimin-
ished number of cross-bridges formed during a con-
tractile cycle, leading to diminished contractile force
generation. Several mechanisms may be responsible
for the reduced release of Ca2+. First, there appears to
be a reduction in the trigger Ca2+ current marked by L-
type Ca2+ channel dysfunction. Second, SR calcium
release channels appear to be reduced22,23 or dysfunc-
tional24,25 in severe hypertrophy and/or failure. A sum-
mary of the alterations in Ca2+ dynamics that occur in
myocyte hypertrophy and/or failure appears in Fig 2. 
The fundamental contractile unit of the myocyte is the
sarcomere. The sarcomere is composed of actin and
myosin filaments, tropomyosin, and the troponin com-
plex: troponin C, troponin I, and troponin T. Although a
Fig 1. The action potential (left panels) and transient outward K+ current (right panels) of normal (top) and fail-
ing (bottom) human ventricular myocytes. A common abnormality associated with myocyte hypertrophy and/or
failure is a prolongation of the action potential. The transient outward K+ current density (Ito) was reduced in fail-
ing human myocytes. A reduction in key K+ currents involved in sarcolemmal repolarization likely contributes to
action potential prolongation in hypertrophy and/or failure. V, Voltage; pA/pF, picoamps/picofarads. (From
Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH, et al. Sudden cardiac death
in heart failure: the role of abnormal repolarization. Circulation 1994;90:2534-9. Reprinted with permission of
Lippincott Williams & Wilkins.)
390 Walker, Crawford, Spinale The Journal of Thoracic and
Cardiovascular Surgery
February 2000
myosin isoform switch was previously considered to
occur only in animal models of failure,26-29 a recent
study has identified that it occurs in the failing human
myocyte. Specifically, Lowes and associates30 have
reported a reduction in the expression of the cardiac spe-
cific α-myosin heavy chain coupled with a reciprocal
increase in the expression of the β-myosin heavy chain
in severe hypertrophy and failure.30 The β isoform of the
myosin heavy chain causes a slower velocity of shorten-
ing when compared with the α-myosin heavy chain.31
Therefore, these changes in myosin heavy chain expres-
sion with severe hypertrophy and/or failure may directly
contribute to alterations in LV ejection performance.
Although there appears to be no change in cardiac tro-
ponin I in the setting of hypertrophy and/or failure, its
presence in the serum has been used as a marker for
acute myocardial ischemia.32 Interestingly, it appears
that CABG coupled with cardiopulmonary bypass can
be associated with the release of cardiac troponin I.33
The transient loss of troponin I in cardiac myocytes after
CABG may further exacerbate contractile dysfunction in
the setting of hypertrophy and/or failure.
While studies regarding the contractile apparatus in
the setting of severe hypertrophy and/or failure are cur-
rently ongoing, in general terms the myofilament appa-
ratus appears to be structurally intact. In contrast, the
intracellular environment that surrounds the contractile
elements is substantially abnormal in the setting of
hypertrophy and/or failure and is likely to be a major
contributory cause of LV contractile dysfunction.
Fig 2. A schematic of key alterations that can contribute to abnormal excitation-contraction coupling in the hyper-
trophied and/or failing myoctye. In the normal myocyte (left), sarcolemmal depolarization results in a trigger Ca2+
(I
ca
) current through the L-type channel, which activates a bolus release of Ca2+ from the SR calcium release
channels (CRC). The increased cytosolic Ca2+ causes conformational changes in the myofilament apparatus,
which results in cross-bridge formation and sarcomere shorting. Active relaxation consists of Ca2+ re-uptake into
the SR by SR Ca2+ ATPase (SERCA-2). The rate of SR Ca2+ uptake is influenced by the SERCA-2 regulatory pro-
tein phospholamban (PLB). Cytosolic Ca2+ concentrations can be further reduced through the slower actions of
the sarcolemma Na+/Ca2+ exchanger and a sarcolemmal Ca2+ ATPase (not shown). Alterations in the expression
and/or function of key components of the excitation-contraction coupling process may affect Ca2+ handling and
homeostasis with severe hypertrophy and/or failure (right). There is a reduction in the L-type Ca2+ current and/or
expression, which can result in a blunted trigger Ca2+ current and thereby reduce the release of Ca2+ through the
CRC. A reduction in SERCA-2 expression and function have been reported in severe hypertrophy and/or failure,
which would result in two consequences. First, a reduction in SERCA-2 would result in a reduced capacity for
SR CA2+ re-uptake. Second, stoichiometric alterations between SERCA-2 and PLB would result in reduced
SERCA-2 sensitivity to Ca2+. The slowed removal of Ca2+ from the intracellular compartment would result in an
increase in diastolic Ca2+. Furthermore, the Na+/Ca2+ exchanger is up-regulated, presumably as a compensatory
mechanism (albeit slower) to remove cytosolic Ca2+ levels. 
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Active relaxation. The resequestration of Ca2+ into
the SR occurs primarily through the actions of SERCA-
2 and the influence of the regulatory protein phospho-
lamban. The regulatory influence of phospholamban on
SERCA-2 is dependent on the phosphorylation state.
When phosphorylated, phospholamban enhances
SERCA-2 Ca2+ affinity and uptake, whereas dephos-
phorylated phospholamban diminishes SERCA-2 Ca2+
function. Defects in the resequestration of Ca2+ into the
SR have been clearly identified in severe hypertrophy
and/or failure, which is manifested by increased intra-
cellular diastolic Ca2+.34-37 At the myocardial level,
defects in Ca2+ homeostasis will result in a slowed LV
myocardial relaxation. Furthermore, defects in SR Ca2+
re-uptake would result in increased diastolic Ca2+ con-
centrations, which, in turn, cause decreased sensitivity
of the contractile apparatus to intracellular Ca2+ con-
centrations. Alterations in Ca2+ resequestration that
occur in severe hypertrophy and/or failure are likely
due to several factors. The majority of studies have
reported decreased protein expression and/or function
of SERCA-2 in severe hypertrophy and/or failure.38-42
For example, Hasenfuss and associates41 reported a
36% reduction in SERCA-2 protein levels in the failing
human myocardium. In a recent study by Dillman,43
cardiac myocytes were transfected with DNA for
SERCA-2, which resulted in increased synthesis and
protein levels. The enhanced protein expression of
SERCA-2 in this study increased Ca2+ re-uptake.43 This
in vitro study emphasizes the importance of the loss of
expression and function of SERCA-2 on Ca2+ home-
ostasis. Although it appears that SERCA-2 is reduced
in severe hypertrophy and/or failure, the changes in the
regulatory protein phospholamban appear to be more
complex. In animal models of hypertrophy and failure,
a reduction in the expression of phospholamban has
been documented.44 In human studies, a reduction in
messenger RNA (mRNA) phospholamban levels has
been reported,39,45,46 but absolute protein levels appear
to be unchanged in severe hypertrophy and/or fail-
ure.39,46,47 This may represent an imbalance in the tran-
scription and/or translation rates of phospholamban in
severe hypertrophy and/or failure. Nevertheless, if
SERCA-2 levels decrease without a comparable
change in phospholamban expression, alterations in the
stoichiometry between these proteins can result. Using
transfection techniques, Hajjar and colleagues48 over-
expressed the phospholamban protein in cardiac
myocytes. The increased ratio of phospholamban to
SERCA-2 resulted in slowed Ca2+ re-uptake into the
Fig 3. Intracellular free Ca2+ levels of normal myocytes before and after simulated hyperkalemic cardioplegic
arrest and rewarming. Intracellular Ca2+ levels increased from baseline as cardioplegic arrest was induced, and
the increase persisted through the early reperfusion period. The increased intracellular Ca2+ induced by the depo-
larizing cardioplegic arrest may have particular relevance in the setting of hypertrophy and/or failure. (From
Dorman BH, Hebbar L, Clair MJ, Hinton RB, Roy RC, Spinale FG. Potassium channel opener–augmented car-
dioplegia: protection of myocyte contractility with chronic left ventricular dysfunction. Circulation 1997;96[9
Suppl]:II253-9. Reprinted with permission of Lippincott Williams & Wilkins.)
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SR and increased resting Ca2+ concentrations. These
studies demonstrate the importance of the phospholam-
ban/SERCA-2 stoichiometric relationship in maintain-
ing SR Ca2+ re-uptake and intracellular Ca2+ concentra-
tions, a relationship that may be altered in the setting of
severe hypertrophy and/or failure.
The slower Na+/Ca2+ exchanger also participates in
the extrusion of cytosolic Ca2+ during active relaxation.
There appears to be up-regulation of the Na+/Ca2+
exchanger gene expression and activity in hypertrophy
and/or failure.49-52 The up-regulation of this protein may
initially serve as a compensatory mechanism resulting
from the reduction of SERCA-2 function. This may
eventually result in an overall reduction in the amount
of cytosolic Ca2+ available for SR uptake and subse-
quent release for excitation-contraction coupling. 
SR re-uptake of cytosolic Ca2+ is an energy-depen-
dent process.4 Therefore increased intracellular Ca2+
levels will require increased hydrolysis of ATP for rese-
questration and maintenance of a normal resting
cytosolic Ca2+ concentration. In hypertrophied myo-
cardium, reduced basal levels of high-energy phos-
phates such as ATP have been reported.53 This reduc-
tion in intrinsic levels of high-energy phosphates will
also impede energy-dependent resequestration of Ca2+
and thereby cause increased cytosolic Ca2+ levels in
hypertrophy and/or failure.54 Hypothermic, hyper-
kalemic cardioplegic arrest is associated with an
increase in intracellular Ca2+.55-57 For example, in an in
vitro model of cardioplegic arrest and rewarming,
increased intracellular Ca2+ levels have been recorded,
which persisted in the early reperfusion period (Fig
3).55 Furthermore, additional studies with cardioplegic
arrest and rewarming have reported a prolongation of
the isovolumic pressure decline,58,59 indicative of
abnormalities in myocyte active relaxation. Thus con-
ventional cardioplegic arrest may alter Ca2+ homeosta-
tic mechanisms, which can persist in the early reperfu-
sion period. These alterations in Ca2+ homeostasis may
exacerbate pre-existing abnormalities in severe hyper-
trophy and/or failure which, in turn, would contribute
to LV dysfunction in the early postoperative period. 
Myocyte receptor systems
A number of sarcolemmal receptor systems are
affected with the development of hypertrophy and/or
failure.60-62 This review will focus on the prototypical
β-adrenergic receptor (β-AR) system as it is the recep-
tor system most often pharmacologically manipulated
in the early postoperative setting. Under ideal circum-
stances, intracellular phosphorylation targets after β-
AR stimulation are the L-type Ca2+ channel, phospho-
lamban, and troponin I of the contractile apparatus.
Thus alteration in the expression, function, and/or acti-
vation of the β-AR system will influence key compo-
nents of the excitation-contraction coupling process,
thereby affecting myocyte contractile function. In
hypertrophy and/or failure, a decrease in β-AR density
has been reported. For example, Bristow and associ-
ates63 reported a 62% reduction of the β1 receptor sub-
type in failing human myocardium. This may be in
response to a persistent elevation of circulating cate-
cholamines that can occur in the latter stages of hyper-
trophy and/or failure.64,65 In addition, there appears to
be a reduction in the ability of existing β1 receptors to
respond to circulating catecholamine levels.66-68 This
has been defined as receptor densensitization.69-71 This
desensitization of available β1 receptors appears to be
multifactorial, which includes alterations both at the
level of the receptor and at intracellular transduction
pathways. Seconds to minutes after β-AR exposure to
receptor agonist, phosphorylation of the β-AR by
receptor-associated kinases may occur, resulting in
receptor uncoupling.66,69,72 A further downstream
mechanism for alterations in β-AR signaling is likely
to be due to alterations in the guanine nucleotide–
dependent coupling protein (G protein). Although stud-
ies do not report a change in the density of the stimula-
tory G protein in severe hypertrophy and/or failure,73-75
studies have shown an increase in the density of the
inhibitory G protein76-78 that would result in a reduc-
tion of adenylate cyclase activity. In addition, an appar-
ent desensitization of adenylate cyclase has been
reported, which would further diminish β-AR–mediat-
ed contractility.79 Thus, although a number of defects
exist in the β-AR with severe hypertrophy and/or fail-
ure, the end result will be diminished cyclic adenosine
monophosphate production which, in turn, will influ-
ence contractile performance in the setting of hypertro-
phy and/or failure. 
Increased sympathetic activity and the resultant
increase in plasma catecholamines commonly occurs in
the cardiac surgical setting and may contribute to β-AR
desensitization.80-82 Using atrial myocardial specimens,
Booth and colleagues83 reported diminished adenylate
cyclase activity after cardiopulmonary bypass with β-
AR stimulation. In an isolated myocyte system of
hyperkalemic cardioplegic arrest, reduced contractile
response to the β-AR system has been demonstrated
after reperfusion and rewarming.55,84 A representative
contraction profile of isolated myocytes under normoth-
ermic conditions and after simulated cardioplegic arrest
is shown in Fig 4. Although exposure to the β-receptor
agonist isoproterenol resulted in an overall increase in
myocyte contractility, this response was blunted after
cardioplegic arrest and rewarming. This is indicative of
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 2
Walker, Crawford, Spinale 393
a reduction in β-AR response to receptor stimuli. Thus
the diminished β-AR response that may exist in patients
with pre-existing hypertrophy and/or failure may be fur-
ther reduced in the setting early after cardiac surgery.
Myocyte cytoskeleton
The extramyofilament cytoskeleton of the myocyte
provides a structural framework for myofibrillar assem-
bly and contributes to sarcomere alignment and the
transduction of sarcomere shortening into overall
myocyte shortening. The cytoskeletal network ranges
from the largest components, microtubules (25 nm), to
endosarcomeric proteins at a size of 2 nm. It has been
demonstrated that increased β-tubulin occurs in the
hypertrophied myocyte isolated from patients and ani-
mal models of severe pressure overload in the adult.85
This increase in microtubule density has been reported
with severe hypertrophy to be a compensatory response
for heightened stress placed on the myocardium.
Furthermore, the increased density of the microtubule
network within the myocyte may actually impair con-
tractile performance in hypertrophy and/or failure.86,87
These studies have provided evidence that increased
microtubule network density could cause a viscous
resistive load impeding sarcomere shortening. Indeed,
maneuvers that alter microtubule stability at the level of
the isolated myocyte influence contractility. For exam-
ple, when microtubules are depolymerized in pressure-
overload hypertrophy, contractility returns to normal.85
Of interest, hypothermic exposure caused microtubule
reorganization in hypertrophied and normal myocytes,
which affects contractile function.86 When pressure-
overloaded myocytes were exposed to profound
hypothermic conditions, microtubule depolymerization
occurred. With subsequent warming, the contractile
function of the hypertrophied myocytes was normal-
ized, indicative of an improvement in contractile func-
tion (Fig 5). Thus hypothermia and cardioplegic arrest
in hypertrophied myocardium may influence micro-
tubule stability and thereby contractile performance
with reperfusion and rewarming. However, these issues
remain speculative and warrant further study. 
Congestive heart failure
Congestive heart failure (CHF) is a constellation of
signs and symptoms including peripheral and pul-
monary edema, fatigue on minimal exertion, and short-
ness of breath. CHF is an insidious disease process that
progresses over time and, therefore, should be consid-
ered a chronic disease state. After an initial myocardial
Fig 4. A representative contractile profile of a control myocyte under normothermic conditions (left panel) and
after cardioplegic arrest (right panel). Myocytes were stimulated at 1 Hz by means of methods described previ-
ously.16,55,84 In normothermic control myocytes, a robust increase in contractile performance was observed after
β-receptor stimulation. After hypothermic, cardioplegic arrest, steady-state myocyte contractility was reduced in
comparison with normothermic control conditions. Furthermore, β-adrenergic stimulation after cardioplegia
resulted in a blunted contractile response. These results indicate alterations in the β-adrenergic signaling pathway
after hypothermic cardioplegic arrest. Thus the reduction in the β-adrenergic response that may exist in hyper-
trophied and/or failing myocardium may be heightened and/or exacerbated in the cardiac surgical setting.
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insult, mechanisms are invoked that attempt to com-
pensate for the intrinsic decline in LV myocardial con-
tractility. Early compensatory symptoms may be mini-
mal or nonexistent in these initial stages of the CHF
process. However, sustained activation of these com-
pensatory mechanisms can actually contribute to
and/or accelerate the progression of CHF. One of the
more notable compensatory response mechanisms in
the CHF process is the activation of neurohormonal
axes.88-90 These include the sympathetic adrenergic
system, the renin-angiotensin-aldosterone system, and
the endothelin system.
Activation of the sympathetic adrenergic system is a
hallmark feature of disease progression in CHF.91-93 In
the initial stages of CHF, increased catecholamine pro-
duction has been postulated to serve as a compensato-
ry mechanism for the intrinsic reduction in LV myocar-
dial contractile performance. Plasma catecholamines
rise in a temporal manner in CHF, and significantly
elevated levels have been shown to be a prognostic
index of disease severity and progression.94,95 For
example, a relationship exists between plasma cate-
cholamines and survival.96,97 Prolonged exposure to
elevated plasma catecholamines and, in turn, chronic
activation of the β-AR system can result in a number of
deleterious consequences. As discussed earlier in this
review, sustained β-AR activation can result in β-AR
desensitization and subsequent down-regulation of the
β1 receptor.66-71 The effects of sympathetic adrenergic
activation may contribute to LV myocardial remodeling
and hypertrophy and, therefore, structurally contribute
to CHF. In addition, excessive local production and/or
release of norepinephrine concentrations can be delete-
rious to cardiac myocyte viability. Isolated cardiac
myocyte studies have shown concentration-dependent
effects of norepinephrine on cell death possibly
through apoptosis.98,99 Finally, the activation of the
sympathetic adrenergic system enhances the produc-
tion and release of other potent vasoactive peptides,
particularly angiotensin II and endothelin-1.96,100
Since increased sympathetic adrenergic activity was
viewed as an appropriate compensatory mechanism,
early attempts were made to augment these effects
through direct activation of the β-AR by oral agonists
or phosphodiesterase inhibitors, which increased the
levels of circulating adenosine monophosphate.101,102
The rationale was to increase intrinsic myocardial con-
tractility and thereby improve overall LV ejection per-
formance. Short-term treatment with β-AR agonists or
phosphodiesterase inhibitors resulted in an improve-
ment in LV function and symptoms.103 However, these
effects lessened as treatment continued, and long-term
clinical trails demonstrated increased mortality after
several months of therapy.104,105 These observations led
to the hypothesis that overstimulation of the β-AR sys-
tem may be deleterious and that β-AR blockade may be
beneficial. This concept emerged slowly since it
appeared counterintuitive to inhibit a mechanism that
positively influenced myocardial contractility.106 In
fact, the acute response after initiation of a β-AR antag-
onist was the predicted negative inotropic effect and
transient worsening of CHF symptoms.107 However,
studies have demonstrated that long-term treatment
with β-AR antagonists resulted in improved LV ven-
tricular function, as well as reduced mortality.108 Most
recently, the nonselective β-AR antagonist carvedilol
has been approved for the treatment of mild to moder-
ate CHF.109-111 In addition to directly demonstrating
Fig 5. The effects of hypothermia on the extent (top) and
velocity (bottom) of sarcomere shortening in normal left ven-
tricular (LV) and hypertrophied right ventricular (RV) feline
cardiac myocytes. After hypothermic exposure (<10°C) and
rewarming, the extent and velocity of sarcomere shortening
in hypertrophied myocytes was normalized. These changes
are associated with alterations in cytoskeletal tubulin poly-
merization. PA, Pulmonary artery. (Reprinted with permis-
sion from Tsutsui H, Ishihara K, Cooper G IV. Cytoskeletal
role in the contractile dysfunction of hypertrophied
myocardium. Science 1993;260:682-7, copyright 1993
American Association for the Advancement of Science.)
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that prolonged sympathetic activation contributes to the
CHF process, the institution of β-AR antagonists in the
pharmacologic armamentarium of patients with CHF
may present a new challenge in intraoperative manage-
ment after cardiac surgery. 
Activation of the renin-angiotensin-aldosterone sys-
tem is also a hallmark of severe chronic CHF.112 Renin
cleaves the angiotensin proform, angiotensinogen, to
angiotensin I. Angiotensin II is then formed through the
cleavage of angiotensin I by angiotensin-converting
enzyme, or ACE. Angiotensin II acts both as a direct
vasoconstrictor of vascular smooth muscle cells and in
conjunction with the sympathetic adrenergic system to
increase vascular tone.113-115 Angiotensin II can cause
increased circulating volume through fluid and sodium
retention.113,116,117 Finally, angiotensin II appears to have
trophic and mitogenic effects at the cellular level.118,119
In patients with CHF who have systolic dysfunction,
the administration of ACE inhibitors reduces afterload
and LV wall stress.120-123 These beneficial loading
effects of ACE inhibition result in increased LV ejec-
tion performance. ACE inhibitors also promote sodium
excretion through the reduction in aldosterone and
vasopressin production. In addition, ACE inhibitors
may influence myocardial remodeling by blocking the
mitogenic effects of angiotensin II on cardiac myocytes
and fibroblasts.124-127 Several clinical CHF trials have
demonstrated that ACE inhibition reduced overall mor-
tality, primarily through a reduction in the progression
of the CHF disease process.128-131 Thus ACE inhibition
provides beneficial effects on LV function and myocar-
dial remodeling and has become the standard of treat-
ment for patients with CHF. 
In patients with CHF, aldosterone levels may increase
by over 20-fold compared with normal levels.132 A
recent clinical study examined the effects of the aldos-
terone receptor antagonist, spironolactone, in the set-
ting of CHF.133 The results from this study demonstrat-
ed an additive beneficial effect when spironolactone
was used in conjunction with standard ACE inhibitor
therapy.133 Thus new pharmacologic strategies are
becoming available that can selectively modulate spe-
cific neurohormonal receptor systems and may have
particular relevance in patients presenting with severe
hypertrophy and/or CHF for cardiac surgery.
The endothelins are a family of bioactive peptides
consisting of three isoforms: endothelin-1, endothelin-
2, and endothelin-3, with endothelin-1 being the most
potent and biologically active.134 Specifically, through
the activation of the endothelin A receptor subtype,
endothelin-1 can cause significant and prolonged con-
striction of vascular smooth muscle.135 Thus endo-
thelin-1 is involved in the regulation of systemic and
pulmonary vascular resistance properties. The vaso-
constrictive properties of endothelin-1 are exemplified
by clinical studies that have demonstrated that endothe-
lin-1 receptor blockade significantly reduces systemic
vascular resistance in hypertension.136 Moreover, the
profound effects of endothelin-1 with respect to pul-
monary vascular resistance were demonstrated by the
involvement of this bioactive peptide in the setting of
primary pulmonary hypertension.137 In the setting of
CHF, endothelin-1 production is increased and, as
such, has been implicated to directly contribute to the
progression and/or exacerbation of the disease
process.138 In fact, a nonselective endothelin receptor
antagonist, bosentan, has been successfully used in
patients with CHF, resulting in a reduction in systemic
and pulmonary vascular resistance.139,140
Endothelin-1 receptor stimulation activates a number
of intracellular signaling pathways that continue to be
an area of active investigation.141-144 The downstream
events of endothelin-1 stimulation with respect to the
myocyte are likely to involve activation the Na+/H+
exchanger as well as several Ca2+ regulatory process-
es.145-147 The end result of endothelin-1 receptor stim-
ulation in normal myocytes is an increase in contractile
performance. However, in the context of LV failure,
endothelin-1 receptor activation results in a reduction
in contractility.148,149 The negative inotropic effects of
endothelin-1 with pre-existing LV failure is likely the
result of the exacerbation of intrinsic defects in Ca2+
homeostasis. Thus, in patients with CHF admitted for
cardiac surgery, the systemic and myocardial effects of
endothelin-1 may have particular importance. 
Future directions
An important consideration in preventing further alter-
ations in ionic currents and Ca2+ homeostatic mecha-
nisms in the hypertrophied and/or failing myocardium
would be to alter extracellular stimuli that could influ-
ence these intracellular processes. For example, the insti-
tution of cardiopulmonary bypass results in the activa-
tion of several neurohormonal systems, including the
sympathetic adrenergic system, as well as the synthesis
of bioactive peptides that persist in the postoperative
period.150-152 Heightened sympathetic adrenergic activi-
ty and the resulting release of catecholamines with
respect to the effects on the β-AR system have been dis-
cussed earlier in this review. With respect to bioactive
peptides, plasma levels of endothelin-1 have been shown
to be increased during cardiopulmonary bypass, and
these elevations persist into the postoperative period.152
Thus, in patients with pre-existing hypertrophy and/or
CHF, increased endothelin-1 levels in the setting of car-
diopulmonary bypass may directly contribute to LV
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myocardial dysfunction by direct negative inotropic
effects. More recently, endothelin-1 receptor antagonists
have been developed and successfully used in patients
with LV pump dysfunction.153,154 Thus new pharmaco-
logic strategies are becoming available which can selec-
tively modulate specific receptor systems that may have
particular relevance in patients presenting for cardiac
surgery with severe hypertrophy and/or CHF. 
Summary 
As the number of patients with pre-existing myocar-
dial hypertrophy and/or CHF increases, the elucidation
of mechanisms that potentially contribute to LV dys-
function after cardiac surgery is warranted. The results
from recently performed studies, some of which have
been reviewed here, suggest that underlying contribu-
tory factors for the exacerbation of LV dysfunction in
patients with pre-existing hypertrophy and/or failure in
the postoperative cardiac setting are changes in ionic
currents and Ca2+ homeostasis. Therefore strategies
that are focused on these ionic defects in LV hypertro-
phy and/or failure may have therapeutic benefit in the
cardiac surgical setting. For example, the induction of
myocardial electrical quiescence and cardioplegic
arrest has been successfully achieved through the use
of potassium channel openers that maintain the nega-
tive resting membrane potential of the myocyte.55 In
isolated myocyte systems, the use of potassium channel
openers has been demonstrated to prevent intracellular
Ca2+ accumulation during the cardioplegic arrest peri-
od, which translated into reduced cytosolic Ca2+ levels
with reperfusion and rewarming.55 Furthermore, the
use of potassium channel openers in the intact LV has
been demonstrated to maintain indices of LV ejection
performance with reperfusion and rewarming in the
setting of cardiopulmonary bypass.155 Thus strategies
that facilitate cardioplegic arrest without detrimental
effects on ionic currents and intracellular Ca2+ dynam-
ics may have important implications with pre-existing
LV hypertrophy and/or failure.
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